

NEW

Quality in Health Care

Editor: Diana Mess

Quality in Health Care

is a new quarterly scientific journal being launched in March 1992 by the BMJ to reflect and report initiatives to improve quality of health care, from **everybody** involved in health care.

The Journal aims to monitor:

- The relationship between clinical and medical audit and quality assurance programmes
- The development of clinical and medical audit as local activities and as larger national initiatives
- The integration of medical audit into medical practice
- The impact of medical and clinical audit on postgraduate and undergraduate training and education
- The relationship between management and quality initiatives

To receive more information and a sample copy complete the order form below:

Order Form

QUALITY IN HEALTH CARE ISSN: 0963-8172

PUBLICATION: Quarterly

SUBSCRIPTION RATE: INSTITUTIONAL: £75, \$131 (USA ONLY)
 *PERSONAL £45, \$78 (USA ONLY)

Please tick

- Please enter my subscription, start date _____
- Please send me a sample copy
- Please send me *Instructions to Authors*
- I enclose a cheque for _____
(Payable to British Medical Journal)
- I wish to pay by credit card.

American Express/Visa(Barclaycard)/Mastercard *(Delete as appropriate)*

* Personal Rates are only available on orders placed directly with the Publisher and paid for out of personal funds.

Card Number

MasterCard users should add the numbers appearing above their name

Expiry date _____

Signature _____
(Your signature is essential, especially when paying by credit card)

Name (Capitals) _____

Address _____

_____ **Date** _____

Send orders to:

BMJ Publishing Group, BMA House, Tavistock Square, London. WC1H 9JR.
or BMJ Publishing Group, Box No 560B, Kennebunkport, Maine 04046, USA.

MSSVD

The Medical Society for the Study of Venereal Diseases

President: Dr J R W Harris

St Mary's Hospital, London W2 1NY

The object of the Society is to bring together those interested or engaged in the diagnosis, treatment, and community medical aspects of sexually transmitted diseases. The Society meets regularly in London at the Royal Society of Medicine for the reading of papers, discussions, and presentation of cases. An out-of-London meeting is held in the Spring. Annual subscription for membership of the Society is £50.

Applications for membership are welcome and forms can be obtained from the Honorary Secretary, Dr M J Godley, Florey Unit, Royal Berkshire Hospital, Reading RG1 5AN.

1992 SCIENTIFIC PROGRAMME

at the Royal Society of Medicine,
 1 Wimpole Street, London W1M 8AE

6.30 for 7 pm (unless otherwise stated)

Members and Guests welcome

18-21 June 1992 Spring Meeting, Dublin, Eire
 Local Organiser: Dr F Mulcahy

1992-93 SCIENTIFIC PROGRAMME

Dates are as follows:

- | | |
|-------------|---|
| 1992 | 23 October
13 November |
| 1993 | 22 January
12 February
12 March
16 April
6-9 May Spring Meeting, Zurich |

(Programme to be announced)

ABBREVIATED PRESCRIBING INFORMATION

Warticon: Podophyllotoxin 0.5% w/v. **Presentation:** An acidic ethanolic solution of 0.5% w/v podophyllotoxin. **Uses:** For the treatment of penile warts (condylomata acuminata), located in the preputial space. **Dosage and Administration:** The affected area should be washed and dried prior to application. Using the applicator provided, the warts should be painted twice daily for 3 days. The treated area should be allowed to dry. Treatment may be repeated after 7 days. Maximum single dose of 30 loops per application for home treatment (50 loops under medical supervision). When lesions are greater in area than 4cm², it is recommended that treatment takes place under the direct supervision of medical staff. **Contraindications, Warnings etc:** Open wounds, hypersensitivity to podophyllotoxin. In the event of the preparation entering the eye, the eye should be thoroughly bathed in water. **Side effects:** Local irritation may occur. In the majority of cases, the reactions are mild. **Overdosage:** No overdosages have been reported. No specific antidote is known. Following accidental spillage, wash the affected area with soap and water. In the event of accidental ingestion, give emetic or stomach washout. Treatment should be symptomatic. **Pharmaceutical Precautions:** Store at room temperature. **Package Quantities:** Bottles containing Warticon 3ml. Plastic applicators are also enclosed in each pack. Each loop will carry 5 loops. **Warticon Solution. Leg. Category:** POM. **Basic NHS Cost:** 3 ml £16.00. **Product Licence Number:** PL 3863/0007.

REFERENCES

1. Pickering RW. Br J Sex Med 1989; 16: 320-324.
2. Lassus A, et al. Eur J Sex Trans Dis 1984; 2: 31-33.
3. von Krogh G. In Derm in Five Continents. Proceedings of the XVII World Congress of Dermatology 1987: 317-326.



When getting back
to the clinic becomes
a little difficult

Warticon is a highly effective treatment for male genital warts situated in the preputial space.^{1,2,3}

It can be applied by the patient, in his own home, twice daily for three days, following an initial visit to a GUM clinic.


Warticon therefore relieves the patient, and the clinic, of the time and effort of regular attendance for treatment.¹

Warticon
podophyllotoxin 0.5% w/v

Simple enough for self-application in
male genital warts

 **Perstorp Pharma**

Further information is available from: Perstorp Pharma Ltd, Intec 2, Wade Road, Basingstoke, Hants RG24 0NE Tel: (0256) 477868

 and Warticon are registered trademarks

Your patients rely on you...

To provide the most accurate diagnosis and effective treatment, you need the most current, comprehensive information available. This journal will help you deal with the panic...anxiety...and often misinformation of the patients coming to you concerning sexually transmitted disease.

Identify those at risk

Diagnose infected patients


Provide facts and advice for those who feel threatened

Treat your patients with the most effective therapies

Your source is **Sexually Transmitted Diseases**


Published bi-monthly, *Sexually Transmitted Diseases* brings you the most up-to-date information on sexually transmitted diseases and related topics. Original articles keep you abreast of the latest advances in diagnosis and treatment, patient education, public health issues, etiology and pathology. Newly identified syndromes and disease entities are covered in each issue, along with notes from the CDC and NIH, case reports, and AVDA News.

Subscribe to the resource you can rely on for the latest, most authoritative information on STDs!



No-Risk Guarantee!

If you're not completely satisfied, you may cancel your subscription at any time and receive a refund for all unmailed issues.

 Call us today TOLL FREE
1-800-638-3030 (U.S. except AK)
or FAX your order 301-824-7390.

Published bi-monthly
Annual subscription rates:
Individual \$100.00 (U.S.) - \$115.00 (Other countries)
Institution \$145.00 (U.S.) - \$180.00 (Other countries)

Published by

J. B. Lippincott

A **Wolters Kluwer** Company




Journals Division
J. B. Lippincott
227 East Washington Square
Philadelphia, PA 19106-3780
USA

...and you can rely on Sexually Transmitted Diseases

Journal of the American Venereal Disease Association
Julius Schachter, PhD, Editor

What's best for patients?




New drugs are continually being developed and knowledge about existing drugs is constantly expanding, so it is essential, but difficult, for doctors to keep up to date with the latest developments. *New Drugs* describes the most important therapeutic advances of the past decade and discusses the drugs that will be in common use in the 1990s. Completely revised and updated, this second edition has been expanded to include 11 additional chapters. Its coverage of practical aspects of drug use, avoidance of adverse reactions and interactions, and prescribing at extremes of age makes it an invaluable guide for busy practitioners who want to get the best out of the new drugs currently available.

Chapters include: Adverse reactions to drugs • Calcium antagonists
• Diuretic treatment • Antiarrhythmic drugs • Insulin • Lipid lowering drugs
• Antidepressant drugs • Centrally acting drugs • Controlling symptoms in advanced cancer

Second edition April 1991

UK £14.95; Abroad £18.00 (BMA members £13.95 or £17.00)



Doctors do not always agree on what is the right treatment even for quite common conditions. Often definitive clinical trials have not been performed and no one knows for sure the best way to treat. *Controversies in Therapeutics* looks at some problems that arise in general practice. For each one it offers two different approaches; and Peter Rubin, professor of therapeutics and consultant physician at the University Hospital of Nottingham, provides an editorial comment on these which summarises the prevailing views and helps you to make up your own mind. Written by academic experts with everyday clinical experience, *Controversies in Therapeutics* is a must for all physicians and general practitioners—both those who think they know it all and those who know they don't.

Chapters include: Role of diet in treating atopic eczema • Risks of dependence on benzodiazepine drugs • Thrombolysis and the general practitioner
• Depression in childhood • Theophylline in the management of airflow obstruction • Management of constipation

January 1991

UK £9.95; Abroad £12.00 (BMA members £8.95 or £11.00)



ORDER FORM **British Medical Journal, PO Box 295, London WC1H 9JR.**

Please send me the following books:

QTY	TITLE	AUTHOR/EDITOR	AMOUNT

Prices include postage, by air abroad

TOTAL £

NAME _____
(print clearly)

Membership No _____

ADDRESS _____

Cheque enclosed (made payable to British Medical Journal) £ _____

Debit my AMERICAN EXPRESS/VISA/MASTERCARD

Card No _____ Exp _____


POSTCODE _____

Signature _____

BMJ books are also available from major booksellers or the BMJ bookshop in BMA House.

Please send me a book catalogue

Prescribing information *Indications and dosage:* Systemic candidiasis: 400mg on the first day followed by 200-400mg once daily. Cryptococcosis, including meningitis: 400mg on the first day followed by 200-400mg once daily. Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with AIDS: 100-200mg daily. Oropharyngeal candidiasis: 50-100mg once daily for 7-14 days or longer in immunocompromised patients. Other mucosal candidal infections: 50-100mg once daily for 14-30 days. Vaginal candidiasis: single 150mg dose. Prevention of fungal infections in neutropenic patients following cytotoxic chemotherapy or radiotherapy: 50-100mg once daily whilst patients are predisposed to such infections. Use in the elderly - as above except for those renally impaired - see data sheet. Use in children - not recommended. *Administration:* Diflucan may be administered either orally or by intravenous infusion at a rate of approximately 5-10ml/min. The dosages for the two routes are equivalent. *Contra-indications:* Hypersensitivity to fluconazole or related triazoles, pregnancy and women of childbearing potential unless adequate contraception is employed. *Warnings:* Lactation - not recommended. Renal impairment: dosage reduction may be necessary, see data sheet. *Drug interactions:* Monitor patients on concurrent anticoagulants, oral sulphonylureas, phenytoin or cyclosporin, rifampicin or theophylline. *Side-effects:* Nausea, abdominal discomfort, diarrhoea, flatulence and anaphylaxis. *Package Quantities and Basic NHS cost:* 50mg capsule, calendar pack of 7, £16.61 (PL 57/0289); 200mg capsule, calendar pack of 7, £66.42 (PL 57/0317); 150mg capsule, pack of 1, £7.12 (PL 57/0290); Powder for Oral Suspension, 35ml after reconstitution with water: Bottle of 50mg/5ml, £16.61 (PL 57/0343), Bottle of 200mg/5ml, £66.42 (PL 57/0344); Bottles of 25ml and 100ml containing Diflucan 2mg/ml intravenous infusion - 25ml (50mg) bottle, £7.32; 100ml (200mg) bottle, £29.28 (PL 57/0315). Hospital prices are available on request. *References* 1. Data on file, Pfizer Ltd. 2. Brammer, K.W. (1990), *Haematology and Blood Transfusion*, 33, 546-550. 3. Samonis, G. et al. (1990), *Reviews of Infectious Diseases*, 12(3), S369-S373. 4. Data on file, Pfizer Ltd. 5. Buxton, M.J. et al. (1991), *Journal of Infection*, 23, 17-31. Further information on request. Pfizer Limited, Sandwich, Kent



DIFLUCAN* is a highly effective antifungal agent with activity against a wide range of common invasive fungal infections.¹ It should be considered as a first-line treatment in suspected or proven candidal or cryptococcal infections. DIFLUCAN also provides effective prophylactic therapy in neutropenic patients and in patients with solid tumours.^{2,3}

DIFLUCAN has a good safety profile and is well tolerated in both its oral and intravenous forms.⁴ Since DIFLUCAN is generally better tolerated than I.V. amphotericin B, patients require less hospital care and can be treated on an outpatient basis thus facilitating a substantial reduction in costs.⁵

Diflucan ORAL/I.V. Counters invasive fungal infection.
 fluconazole *Trade Mark